A detailed history of Rafferty Asset Management, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 255,548 shares of NTLA stock, worth $3.09 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
255,548
Previous 225,212 13.47%
Holding current value
$3.09 Million
Previous $5.04 Million 4.19%
% of portfolio
0.02%
Previous 0.02%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$19.72 - $27.36 $598,225 - $829,992
30,336 Added 13.47%
255,548 $5.25 Million
Q2 2024

Aug 13, 2024

SELL
$20.02 - $27.22 $1.97 Million - $2.68 Million
-98,349 Reduced 30.4%
225,212 $5.04 Million
Q1 2024

May 13, 2024

SELL
$23.82 - $32.8 $129,509 - $178,333
-5,437 Reduced 1.65%
323,561 $8.9 Million
Q4 2023

Feb 13, 2024

BUY
$23.16 - $32.34 $1.8 Million - $2.52 Million
77,873 Added 31.01%
328,998 $10 Million
Q3 2023

Nov 13, 2023

BUY
$31.62 - $45.78 $1.35 Million - $1.96 Million
42,757 Added 20.52%
251,125 $7.94 Million
Q2 2023

Aug 11, 2023

SELL
$34.58 - $46.03 $104,431 - $139,010
-3,020 Reduced 1.43%
208,368 $8.5 Million
Q1 2023

May 11, 2023

SELL
$33.3 - $44.82 $768,430 - $1.03 Million
-23,076 Reduced 9.84%
211,388 $7.88 Million
Q4 2022

Feb 13, 2023

BUY
$33.21 - $62.69 $3.48 Million - $6.57 Million
104,805 Added 80.83%
234,464 $8.18 Million
Q3 2022

Nov 14, 2022

BUY
$53.92 - $71.7 $740,860 - $985,158
13,740 Added 11.85%
129,659 $7.26 Million
Q2 2022

Aug 12, 2022

BUY
$38.49 - $76.21 $1.01 Million - $2 Million
26,198 Added 29.2%
115,919 $6 Million
Q1 2022

May 13, 2022

BUY
$58.27 - $118.99 $2.44 Million - $4.98 Million
41,867 Added 87.49%
89,721 $6.52 Million
Q4 2021

Feb 10, 2022

BUY
$100.76 - $138.36 $2.87 Million - $3.94 Million
28,463 Added 146.78%
47,854 $5.66 Million
Q3 2021

Nov 10, 2021

SELL
$132.37 - $176.78 $1.48 Million - $1.98 Million
-11,191 Reduced 36.59%
19,391 $2.6 Million
Q2 2021

Aug 10, 2021

SELL
$60.88 - $161.91 $1.23 Million - $3.28 Million
-20,273 Reduced 39.86%
30,582 $4.95 Million
Q1 2021

May 10, 2021

BUY
$46.59 - $83.68 $1.55 Million - $2.79 Million
33,351 Added 190.53%
50,855 $4.08 Million
Q4 2020

Feb 10, 2021

SELL
$18.83 - $63.53 $1.21 Million - $4.08 Million
-64,161 Reduced 78.57%
17,504 $952,000
Q3 2020

Nov 13, 2020

BUY
$17.47 - $24.93 $1 Million - $1.43 Million
57,319 Added 235.43%
81,665 $1.62 Million
Q2 2020

Aug 07, 2020

BUY
$11.14 - $22.87 $271,214 - $556,793
24,346 New
24,346 $512,000
Q1 2020

May 15, 2020

SELL
$9.44 - $15.58 $429,444 - $708,765
-45,492 Closed
0 $0
Q4 2019

Feb 10, 2020

SELL
$10.43 - $17.67 $614,931 - $1.04 Million
-58,958 Reduced 56.45%
45,492 $667,000
Q3 2019

Nov 14, 2019

BUY
$13.07 - $18.51 $155,010 - $219,528
11,860 Added 12.81%
104,450 $1.39 Million
Q2 2019

Aug 09, 2019

BUY
$13.88 - $18.41 $178,649 - $236,955
12,871 Added 16.15%
92,590 $1.52 Million
Q1 2019

May 15, 2019

BUY
$12.79 - $17.62 $1.02 Million - $1.4 Million
79,719 New
79,719 $1.36 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $920M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.